GAITHERSBURG, Md.--(BUSINESS WIRE)--The emergency use of an investigational drug has yielded promising results in reducing the potentially fatal side effects of the widely used cancer chemotherapy 5-fluorouracil (5-FU), according to clinical data that will be reported June 1 at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando.
